Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseThe ubiquitin proteasomal system: a potential target for the management of Alzheimer's diseaseThe Metamorphic Nature of the Tau Protein: Dynamic Flexibility Comes at a CostChaperones in NeurodegenerationMouse models of frontotemporal dementiaThe role of tau in neurodegenerative diseases and its potential as a therapeutic targetAbnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1The human HSP70 family of chaperones: where do we stand?Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanismsAllostery in the Hsp70 chaperone proteinsCurcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic miceLack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosisIntrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau FragmentationAttenuation of noise-induced hearing loss using methylene blue.Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition.Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementiaPreventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathiesMethylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicityHuman cyclophilin 40 unravels neurotoxic amyloids.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Motor and cognitive deficits in aged tau knockout mice in two background strains.Effect size of memory deficits in mice with adult-onset P301L tau expression.The hunt for gene effects pertinent to behavioral traits and psychiatric disorders: from mouse to human.Methylene blue as a cerebral metabolic and hemodynamic enhancer.Heat shock protein 70 in Alzheimer's diseasePE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease.Tau reduction prevents disease in a mouse model of Dravet syndromeThe toxicity of tau in Alzheimer disease: turnover, targets and potential therapeuticsTolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.Advances in tau-based drug discovery.The earliest tau dysfunction in Alzheimer's disease? Tau phosphorylated at s422 as a toxic seedSynthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance.Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies.Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia.The many faces of tauDnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau.
P2860
Q26739412-8DC79B98-5F18-487B-88D4-CBD6601286A9Q26749321-E94B9F79-601A-4F21-94E2-D77116284B2CQ26772846-7FF2E24B-93E0-4576-86E0-2EB16414D51FQ26782943-A73C1CF3-195E-4712-AF9D-AB1C8AA04195Q26829009-16EF482E-43E4-41EC-B315-A113E32FE783Q27005032-BB43B1DB-4A6C-4B43-8ED6-3200933C93ECQ27314013-7127753F-BB91-4148-97B3-8FBDE0E1A136Q28071416-E07627CE-64F8-43E6-9F9C-19914978641DQ28259424-80144076-4F59-4639-BBBD-CB5110FEF4A0Q28266387-7D3DCED4-8195-4B64-91C4-2528BE0FAFA1Q28282056-63CAE6A0-3A4F-44D0-80AC-4A4F60D6A90AQ28477389-4EF8AF03-05D3-46A3-A94A-12AB087D322DQ28552366-48F5C62F-8E8B-4082-88B0-4CA14038E995Q30439567-BB11D50C-EA1F-4DEA-9A61-801D402BE6C0Q30440318-390C3C43-5942-41DD-812A-2FD1D28F70C2Q30576502-D93B307A-225D-48F9-B69D-94D1AF6B359DQ30649677-41F11988-24EE-4A11-A174-6B6F167984E7Q30669674-AB1E7FC2-9F66-4B1B-ADD4-9646D4B8B940Q33784466-AE4CD923-5660-4BF3-A370-E44A4DFFA23BQ33842022-0DE514DF-212E-45CA-B5AA-74B7EA35AE86Q34066654-5A50300B-A9C5-491F-86C6-7AE2DD65B9D2Q34077327-E239A6A7-0BDB-4EEA-8213-E54DA90978B6Q34117765-23578557-FC4C-459A-9BD9-9D6BC800341EQ34279459-651924C1-D120-4FD5-B752-1A40F8A166A0Q34441680-21CCAC1D-6BF7-4475-B763-35C8BDFF5D33Q34560571-0D0FC674-DF7E-4AFB-B1D1-64F04BEF642AQ35058484-1E837887-FD43-4D9A-B538-2C3691F7C42DQ35064974-202CA1A1-0348-46F0-AE25-63204851BB9DQ35115219-C307A607-C552-4781-9210-43B9E6FF0DFAQ35216140-77D5ACB5-E942-4F19-AAE5-6D88A6F7EE72Q35264520-0AABA8EB-98CF-4D20-B548-7D1FCBBB8485Q35313148-A2A2898D-64ED-4FA7-B251-1B9155FD3BE1Q35321539-C8BDA6B6-7A57-4872-9054-BA5C6E669ED5Q35474158-B18A19D0-5ADD-4A79-A98F-E756BB73811EQ35542753-589943FE-A9C0-48A9-A91C-2BBFE0ED0176Q35558517-F6C9600E-8A42-4F7A-8A2E-A78893AE0669Q35669674-DC5F694A-1C33-4149-9A63-5FAEBE375951Q35741322-B83EC019-1C85-437E-9A21-1F63D8375C9FQ35870359-50F1644E-8D99-4537-9256-75E759B2703BQ36020569-AFAD1FAF-80E5-4BCB-BF1B-AAC211639924
P2860
Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phenothiazine-mediated rescue ...... nd reduced soluble tau burden.
@ast
Phenothiazine-mediated rescue ...... nd reduced soluble tau burden.
@en
type
label
Phenothiazine-mediated rescue ...... nd reduced soluble tau burden.
@ast
Phenothiazine-mediated rescue ...... nd reduced soluble tau burden.
@en
prefLabel
Phenothiazine-mediated rescue ...... nd reduced soluble tau burden.
@ast
Phenothiazine-mediated rescue ...... nd reduced soluble tau burden.
@en
P2093
P2860
P356
P1476
Phenothiazine-mediated rescue ...... nd reduced soluble tau burden.
@en
P2093
Amelia G Johnson
Chad A Dickey
Clara Kraft
Edwin J Weeber
Erin E Congdon
Jason E Gestwicki
Jeffrey R Jones
John C O'Leary
John Koren
Jose F Abisambra
P2860
P2888
P356
10.1186/1750-1326-5-45
P577
2010-11-01T00:00:00Z
P5875
P6179
1032394912